Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer.
Chromosomal Instability
Computational Biology
Disease Progression
Female
Gene Expression Profiling
Genetic Heterogeneity
Genomics
/ methods
Humans
Immunotherapy
Liver Neoplasms
/ genetics
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Mutation
Neoplasm Grading
Neoplasm Staging
Sequence Analysis, DNA
Transcriptome
Tumor Suppressor Protein p53
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
08
04
2019
accepted:
17
10
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Chronic inflammation and chromosome aneuploidy are major traits of primary liver cancer (PLC), which represent the second most common cause of cancer-related death worldwide. Increased cancer fitness and aggressiveness of PLC may be achieved by enhancing tumoral genomic complexity that alters tumor biology. Here, we developed a scoring method, namely functional genomic complexity (FGC), to determine the degree of molecular heterogeneity among 580 liver tumors with diverse ethnicities and etiologies by assessing integrated genomic and transcriptomic data. We found that tumors with higher FGC scores are associated with chromosome instability and TP53 mutations, and a worse prognosis, while tumors with lower FGC scores have elevated infiltrating lymphocytes and a better prognosis. These results indicate that FGC scores may serve as a surrogate to define genomic heterogeneity of PLC linked to chromosomal instability and evasion of immune surveillance. Our findings demonstrate an ability to define genomic heterogeneity and corresponding tumor biology of liver cancer based only on bulk genomic and transcriptomic data. Our data also provide a rationale for applying this approach to survey liver tumor immunity and to stratify patients for immune-based therapy.
Identifiants
pubmed: 31729408
doi: 10.1038/s41598-019-52578-8
pii: 10.1038/s41598-019-52578-8
pmc: PMC6858353
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16930Subventions
Organisme : Intramural NIH HHS
ID : Z01 BC010313
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 BC010876
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 BC010877
Pays : United States
Références
PLoS One. 2016 Nov 4;11(11):e0165681
pubmed: 27814372
Ann N Y Acad Sci. 2013 May;1284:57-61
pubmed: 23651194
Am J Surg Pathol. 2012 Jul;36(7):980-6
pubmed: 22446942
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Nat Med. 2006 Apr;12(4):410-6
pubmed: 16532004
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Nucleic Acids Res. 2008 Sep;36(16):5362-75
pubmed: 18697815
Cancer Immunol Immunother. 2017 Jan;66(1):103-112
pubmed: 27832318
Nat Rev Cancer. 2003 Apr;3(4):276-85
pubmed: 12671666
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6496-505
pubmed: 26561581
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Cell Rep. 2019 Jul 30;28(5):1370-1384.e5
pubmed: 31365877
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Gastroenterology. 2009 Mar;136(3):1012-24
pubmed: 19150350
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Cell. 2017 Jan 26;168(3):542
pubmed: 28129544
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001107
pubmed: 20182618
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Hepatology. 2018 Jul;68(1):127-140
pubmed: 29315726
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
World J Gastroenterol. 2018 Mar 21;24(11):1228-1238
pubmed: 29568203
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Oncoimmunology. 2017 Nov 1;7(2):e1390641
pubmed: 29308318
Cell Mol Immunol. 2017 Oct;14(10):819-829
pubmed: 27321064
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Nature. 2014 Aug 14;512(7513):155-60
pubmed: 25079324
Biol Cell. 2011 Jul;103(7):303-17
pubmed: 21651501
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Nat Rev Genet. 2017 Jul;18(7):395-410
pubmed: 28344341
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Diagn Pathol. 2017 Feb 2;12(1):16
pubmed: 28148293
Nat Commun. 2013;4:2612
pubmed: 24113773
Ann N Y Acad Sci. 2009 Feb;1155:206-21
pubmed: 19250206
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5166-71
pubmed: 9560247